共 62 条
[11]
Nilvebrant L.(1999)Serum protein binding of tolterodine and its major metabolites in humans and several animal species Biopharm Drug Dispos 20 91-9
[12]
Postlind H.(1999)Tolterodine is effective and well tolerated during long-term use in patients with overactive bladder [abstract] J Urol 161 35-43
[13]
Danielson A.(2001)Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder Clin Pharmacokinet 40 135-7
[14]
Lindgren A.(1992)Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population Clin Pharmacol Ther 51 12-65
[15]
Mahgoub J.R.(1997)Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry J Pharm Biomed Analysis 16 155-61
[16]
Idle L.G.(1993)Differences of chronopharmacokinetic profiles between Propranolol and atenolol in hypertensive subjects J Clin Pharmacol 33 756-5
[17]
Dring G.(1995)Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease J Clin Pharmacol 35 1071-905
[18]
Alván P.(1997)Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects Antimicrob Agents Chemother 41 898-63
[19]
Bechtel L.(1997)Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients Pharmacotherapy 17 457-96
[20]
Iselius N.(1999)Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin J Clin Pharmacol 39 289-18